NEW YORK, Sept. 19, 2016 /PRNewswire/ -- Attorney
Advertising -- Bronstein, Gewirtz & Grossman, LLC is
investigating potential claims on behalf of purchasers of the
securities of Spectrum Pharmaceuticals Inc. ("Spectrum" or the
"Company") (NASDAQ: SPPI). Such investors are advised to contact
Peretz Bronstein or his investor
relations analyst Yael Hurwitz at
info@bgandg.com or 212-697-6484.
The investigation concerns whether Spectrum and certain of its
officers and/or directors have violated Sections 10(b) and 20(a) of
the Securities Exchange Act of 1934.
Spectrum dropped over 9%, after it was revealed that the Company
had failed to disclose that the FDA had advised it to not submit a
New Drug Application for its drug candidate apaziquone back in
December of 2012. Only later did Spectrum tell its investors that
"we took this data, met with the FDA, and our understanding is and
our decision is that we can go ahead and file the NDA with this
drug." One journalist wrote, that "was not a fully truthful summary
of the FDA's guidance to Spectrum."
If you are aware of any facts relating to this investigation, or
purchased shares of Spectrum, you can assist this investigation by
visiting the firm's site: http://www.bgandg.com/sppi. You can also
contact Peretz Bronstein or his
Investor Relations Analyst, Yael
Hurwitz of Bronstein, Gewirtz & Grossman, LLC:
212-697-6484 or via email info@bgandg.com. Those who inquire by
e-mail are encouraged to include their mailing address, email and
telephone number.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation
boutique. Our primary expertise is the aggressive pursuit of
litigation claims on behalf of our clients. In addition to
representing institutions and other investor plaintiffs in class
action security litigation, the firm's expertise includes general
corporate and commercial litigation, as well as securities
arbitration. Attorney advertising. Prior results do not
guarantee similar outcomes.
Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/shareholder-alert-bronstein-gewirtz--grossman-llc-announces-investigation-of-spectrum-pharmaceuticals-inc-sppi-300329955.html
SOURCE Bronstein, Gewirtz & Grossman, LLC